ganoderic acid B
Identification
| Name | ganoderic acid B |
| CAS Number | 81907-61-1 |
| FDA UNII | AV74TFJ3IS |
| Molecular Formula | C30 H44 O7 |
| Molecular Weight | 516.67508000 |
| Nikkaji Number | J39.405J |
Regulatory
Physical Properties
| Assay | 95.00 to 100.00 |
| Food Chemicals Codex Listed | No |
| Soluble in | water, 1.905 mg/L @ 25 °C (est) |
No sensory data available
Safety Information
| Oral/Parenteral Toxicity | Not determined |
| Dermal Toxicity | Not determined |
| Inhalation Toxicity | Not determined |
GHS Classification
['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']
Safety in Use
| Category | natural substances and extractives |
| Recommendation for ganoderic acid B usage levels up to | not for fragrance use. |
| Recommendation for ganoderic acid B flavor usage levels up to | not for flavor use. |
BOC Sciences
Best of Chemicals Supplier
Quality supplier of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecul...
Potential Uses
Natural Occurrence
Synonyms
(2R,6R)-6-[(3S,5R,7S,10S,13R,14R,17R)-3,7-
dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
lanost-8-en-26-oic acid, 3,7-dihydroxy-3,11,23-trioxo-, (7beta,15alpha,25R)-
PubMed:
[Ganoderma triterpenoids from aqueous extract of Ganoderma lucidum].
PubMed:
Triterpenoids from
Ganoderma lucidum
inhibit the activation of EBV antigens as telomerase inhibitors.
PubMed:
Network pharmacology analysis of the anti-cancer pharmacological mechanisms of Ganoderma lucidum extract with experimental support using Hepa1-6-bearing C57 BL/6 mice.
PubMed:
A Validated Reverse-Phase HPLC Method for Quantitative Determination of Ganoderic Acids A and B in Cultivated Strains of Ganoderma spp. (Agaricomycetes) Indigenous to India.
PubMed:
Screening and Analysis of the Marker Components in Ganoderma lucidum by HPLC and HPLC-MS
with the Aid of Chemometrics.
PubMed:
Ganoderic acid B's influence towards the therapeutic window of trifluoperazine (TFP).
PubMed:
Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells.
PubMed:
Structural identification of the metabolites of ganoderic acid B from Ganoderma lucidum in rats based on liquid chromatography coupled with electrospray ionization hybrid ion trap and time-of-flight mass spectrometry.
PubMed:
Pharmacokinetics of ganoderic acid D and its main metabolite by liquid chromatography-tandem mass spectrometry.
PubMed:
[Determination of nine triterpenoid acids from Ganoderma lucidum of different producting areas by HPLC].
PubMed:
Quality Difference Study of Six Varieties of Ganoderma lucidum with Different Origins.
PubMed:
Interaction of ganoderic acid on HIV related target: molecular docking studies.
PubMed:
Triterpenoids with neurotrophic activity from Ganoderma lucidum.
PubMed:
Sensitive and selective liquid chromatography-tandem mass spectrometry method for the determination of five ganoderic acids in Ganoderma lucidum and its related species.
PubMed:
[Extraction of triterpenoids from fruiting [corrected] bodies of Ganoderma lucidum by supercritical fluid extraction].
PubMed:
[Advances of pharmacological effects of triterpenes from Ganoderma lucidum].
PubMed:
[Effects of places and stages on the contents of ganoderic acid B from Ganoderma lucidum].
PubMed:
Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum.